Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Skin Res Technol ; 29(4): e13314, 2023 Apr.
Article in English | MEDLINE | ID: covidwho-2293476

ABSTRACT

BACKGROUND: Coronavirus disease 2019 (COVID-19) pandemic has caused changes in the medical practice. However, it is unclear whether the patients receiving phototherapy for their dermatoses have been affected. OBJECTIVES: This study aimed to identify the impact of the COVID-19 pandemic on phototherapy, focusing on the patient profile, adherence, and attitude before and after the surge. METHODS: The study encompassed the time 5 months prior to and after the surge of the COVID-19 pandemic (from May to July, 2021), resulting in the temporary closure of our phototherapeutic unit. RESULTS: Nine hundred eighty-one patients received phototherapy during this period. Vitiligo, psoriasis (Ps), and atopic dermatitis (AD) represented the groups with the highest patient numbers. For vitiligo, Ps and AD, 39.6%, 41.9%, and 28.4% of the patients resumed phototherapy after the pandemic-related shutdown (PRS). No significant difference was noted in age, gender, and number of weekly sessions between those who resumed or stopped phototherapy after PRS among three groups. Patients who resumed phototherapy after PRS tended to receive more weekly sessions of phototherapy than those who initiated after PRS. Additionally, patients who resumed phototherapy showed no significant difference in the number of weekly sessions before and after PRS. CONCLUSIONS: This study reveals a significant impact of the COVID-19 pandemic on patients undergoing phototherapy. Although the patient number remained similar before and after PRS, a significant portion of patients discontinued phototherapy after PRS. New strategies and continued education are needed to improve patient management in times of pandemic.


Subject(s)
COVID-19 , Dermatitis, Atopic , Psoriasis , Ultraviolet Therapy , Vitiligo , Humans , Ultraviolet Therapy/methods , Taiwan/epidemiology , Pandemics , COVID-19/etiology , Phototherapy , Psoriasis/therapy
2.
Sci Rep ; 11(1): 5070, 2021 03 03.
Article in English | MEDLINE | ID: covidwho-1117656

ABSTRACT

Inactivation technology for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is certainly a critical measure to mitigate the spread of coronavirus disease 2019 (COVID-19). A deep ultraviolet light-emitting diode (DUV-LED) would be a promising candidate to inactivate SARS-CoV-2, based on the well-known antiviral effects of DUV on microorganisms and viruses. However, due to variations in the inactivation effects across different viruses, quantitative evaluations of the inactivation profile of SARS-CoV-2 by DUV-LED irradiation need to be performed. In the present study, we quantify the irradiation dose of DUV-LED necessary to inactivate SARS-CoV-2. For this purpose, we determined the culture media suitable for the irradiation of SARS-CoV-2 and optimized the irradiation apparatus using commercially available DUV-LEDs that operate at a center wavelength of 265, 280, or 300 nm. Under these conditions, we successfully analyzed the relationship between SARS-CoV-2 infectivity and the irradiation dose of the DUV-LEDs at each wavelength without irrelevant biological effects. In conclusion, total doses of 1.8 mJ/cm2 for 265 nm, 3.0 mJ/cm2 for 280 nm, and 23 mJ/cm2 for 300 nm are required to inactivate 99.9% of SARS-CoV-2. Our results provide quantitative antiviral effects of DUV irradiation on SARS-CoV-2, serving as basic knowledge of inactivation technologies against SARS-CoV-2.


Subject(s)
SARS-CoV-2/radiation effects , Ultraviolet Therapy/methods , Virus Inactivation/radiation effects , COVID-19/epidemiology , COVID-19/transmission , Humans , SARS-CoV-2/metabolism , Ultraviolet Rays , Virus Diseases/prevention & control
3.
J Drugs Dermatol ; 19(11): 1101-1108, 2020 Nov 01.
Article in English | MEDLINE | ID: covidwho-941793

ABSTRACT

BACKGROUND: Clinical and economic comparisons of therapies for plaque psoriasis are regularly updated following each new devel- opment in the field. With the recent availability of a novel accessory (Multi Micro DoseTM [MMD®] tip) for the 308nm excimer laser (XTRAC®, Strata Skin Sciences, Horsham, PA), which can determine and deliver an optimal therapeutic dose (OTDTM) of ultraviolet-B light in an improved protocol, the need for comparative health-economic assessment recurs. To this end, a comprehensive evaluation of treatment-related costs was undertaken from the payer perspective. Results show that outcomes are influenced by many factors; most importantly, the severity and extent of disease, treatment selection, and patient preference, as well as compliance, adherence, and persistence with care. Among study comparators, the 308nm excimer laser – XTRAC – with its latest MMD enhancement, is safe and delivers incremental clinical benefits with the potential for significant cost savings. These benefits are particularly relevant today in the context of SARS-CoV-2 virus and the COVid-19 pandemic. J Drugs Dermatol. 2020;19(11):1101-1108. doi:10.36849/JDD.2020.5510.


Subject(s)
Coronavirus Infections , Health Care Costs/statistics & numerical data , Pandemics , Pneumonia, Viral , Psoriasis/therapy , COVID-19 , Cost-Benefit Analysis , Humans , Lasers, Excimer/therapeutic use , Patient Compliance , Patient Preference , Psoriasis/economics , Psoriasis/pathology , Severity of Illness Index , Ultraviolet Therapy/economics , Ultraviolet Therapy/methods
5.
Photodiagnosis Photodyn Ther ; 31: 101943, 2020 Sep.
Article in English | MEDLINE | ID: covidwho-693299

ABSTRACT

BACKGROUND: To review the effect of ultraviolet germicidal irradiation (UVGI) as a disinfection method for filtering facepiece respirators (FFRs) to facilitate reuse during COVID-19 pandemic. METHODS: Systematic review of the research concerning UVGI for FFRs disinfection to facilitate reuse (also termed limited reuse) during respiratory infectious diseases where aerosol transmission is considered possible. RESULTS: UVGI is one possible method for respiratory disinfection to facilitate the reuse of dwindling supplies. Appropriate dose UVGI exposition could provide enough energy to effectively decontaminate respiratory viral agents and maintain respirator's integrity for reuse. There was not currently sufficient research evidence on the effect of UVGI to inactivate coronaviruses SARS-CoV-2, and the practical application of UVGI is still unclear. . CONCLUSION: Appropriate dose UVGI exposition could provide enough energy to effectively decontaminate respiratory viral agents and maintain respirator's integrity for reuse. Further evidence concerning UVGI as a decontamination technique specifically for SARS-CoV-2 isneeded.


Subject(s)
Coronavirus Infections/prevention & control , Decontamination/methods , Equipment Contamination/prevention & control , Pandemics/prevention & control , Photochemotherapy/methods , Pneumonia, Viral/prevention & control , Ultraviolet Therapy/methods , Ventilators, Mechanical/virology , COVID-19 , Coronavirus Infections/epidemiology , Equipment Reuse/statistics & numerical data , Humans , Infection Control/methods , Pneumonia, Viral/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL